

# UCLA

## UCLA Previously Published Works

### Title

Mycoplasma genitalium Detection in Urogenital Specimens from Symptomatic and Asymptomatic Men and Women by Use of the cobas TV/MG Test

### Permalink

<https://escholarship.org/uc/item/5sc3c19f>

### Journal

Journal of Clinical Microbiology, 58(6)

### ISSN

0095-1137

### Authors

Van Der Pol, Barbara  
Waites, Ken B  
Xiao, Li  
[et al.](#)

### Publication Date

2020-05-26

### DOI

10.1128/jcm.02124-19

Peer reviewed



# *Mycoplasma genitalium* Detection in Urogenital Specimens from Symptomatic and Asymptomatic Men and Women by Use of the cobas TV/MG Test

Barbara Van Der Pol,<sup>a</sup> Ken B. Waites,<sup>a</sup> Li Xiao,<sup>a</sup> Stephanie N. Taylor,<sup>b</sup> Arundhati Rao,<sup>c</sup> Melinda Nye,<sup>d</sup> Steven Chavoustie,<sup>e</sup> Aaron Ermel,<sup>f</sup> Clair Kaplan,<sup>g</sup> David Eisenberg,<sup>h</sup> Philip A. Chan,<sup>i</sup> Leandro Mena,<sup>j</sup> Sixto Pacheco,<sup>k</sup> Smitha Krishnamurthy,<sup>l</sup> Ruchika Mohan,<sup>l</sup> Rasa Bertuzis,<sup>l</sup> Chris L. McGowin,<sup>l</sup> Rodney Arcenas,<sup>l</sup> Elizabeth M. Marlowe<sup>m</sup>

<sup>a</sup>University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA

<sup>b</sup>Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA

<sup>c</sup>Baylor Scott & White Health, Temple, Texas, USA

<sup>d</sup>Laboratory Corporation of America Holdings, Burlington, North Carolina, USA

<sup>e</sup>Healthcare Clinical Data, Inc., North Miami, Florida, USA

<sup>f</sup>Indiana University School of Medicine, Indianapolis, Indiana, USA

<sup>g</sup>Planned Parenthood of Southern New England, New Haven, Connecticut, USA

<sup>h</sup>Planned Parenthood of St. Louis Region and Southwest Missouri, St. Louis, Missouri, USA

<sup>i</sup>Brown University, Providence, Rhode Island, USA

<sup>j</sup>University of Mississippi Medical Center, Jackson, Mississippi, USA

<sup>k</sup>BioCollections Worldwide, Inc., Miami, Florida, USA

<sup>l</sup>Roche Molecular Systems, Inc., Pleasanton, California, USA

<sup>m</sup>Quest Diagnostics Infectious Disease, San Juan Capistrano, California, USA

**ABSTRACT** *Mycoplasma genitalium* (MG) infections are a growing concern within the field of sexually transmitted infections. However, diagnostic assays for *M. genitalium* have been limited in the United States. As most infections are asymptomatic, individuals can unknowingly pass the infection on, and the prevalence is likely to be underestimated. Diagnosis of *M. genitalium* infection is recommended using a nucleic acid test. This multicenter study assessed the performance of the cobas *Trichomonas vaginalis* (TV)/MG assay (cobas) for the detection of *M. genitalium*, using 22,150 urogenital specimens from both symptomatic and asymptomatic men and women collected at geographically diverse sites across the United States. The performance was compared to a reference standard of three laboratory-developed tests (LDTs). The specificity of the cobas assay for *M. genitalium* ranged from 96.0% to 99.8% across symptomatic and asymptomatic men and women. The sensitivities in female vaginal swabs and urine samples were 96.6% (95% confidence interval [CI], 88.5 to 99.1%) and 86.4% (95% CI, 75.5 to 93.0%), respectively. The sensitivities in male urine and meatal swab samples were 100% (95% CI, 94.0 to 100%) and 85.0% (95% CI, 73.9 to 91.9%), respectively. This study demonstrated that the cobas assay was highly sensitive and specific in all relevant clinical samples for the detection of *M. genitalium*.

**KEYWORDS** cobas TV/MG, *Mycoplasma genitalium*, molecular diagnostics, PCR, genital infection, genital disease

*Mycoplasma genitalium* is a sexually transmitted infection (STI) which has been associated with urethritis, cervicitis, pelvic inflammatory disease, and male and female infertility in epidemiologic studies (1–8). The prevalence of *M. genitalium* infection varies depending on the geographical region, gender, and the presence of risk factors. In the general population, it is estimated to range from 1% to 2% (9–12), and

**Citation** Van Der Pol B, Waites KB, Xiao L, Taylor SN, Rao A, Nye M, Chavoustie S, Ermel A, Kaplan C, Eisenberg D, Chan PA, Mena L, Pacheco S, Krishnamurthy S, Mohan R, Bertuzis R, McGowin CL, Arcenas R, Marlowe EM. 2020. *Mycoplasma genitalium* detection in urogenital specimens from symptomatic and asymptomatic men and women by use of the cobas TV/MG test. *J Clin Microbiol* 58:e02124-19. <https://doi.org/10.1128/JCM.02124-19>.

**Editor** Erik Munson, Marquette University

**Copyright** © 2020 Van Der Pol et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Barbara Van Der Pol, [bvanderp@uab.edu](mailto:bvanderp@uab.edu).

**Received** 9 January 2020

**Returned for modification** 6 February 2020

**Accepted** 12 March 2020

**Accepted manuscript posted online** 25 March 2020

**Published** 26 May 2020

in patients attending sexual health clinics, the estimates range from 3.3% to 38% (2, 13–18).

Many *M. genitalium* infections are asymptomatic, and, therefore, it is possible for individuals to unknowingly transmit the infection to their sexual partners (19–21). Asymptomatic infections can lead to pelvic inflammatory disease, which is associated with serious long-term sequelae, including ectopic pregnancy, infertility, and pelvic/abdominal pain (3, 22; [www.cdc.gov/std/pid/stdfact-pid-detailed.htm](http://www.cdc.gov/std/pid/stdfact-pid-detailed.htm)). The extent to which these sequelae can be attributed to asymptomatic *M. genitalium* infections is unknown, in part due to a lack of sensitive diagnostic tools. *M. genitalium* is difficult to culture, typically requiring several weeks or months, meaning that, historically, *M. genitalium* infections were rarely diagnosed and it was difficult to estimate their prevalence (23; [www.cdc.gov/std/tg2015/emerging.htm#myco](http://www.cdc.gov/std/tg2015/emerging.htm#myco)). *M. genitalium* infections can now be rapidly detected using nucleic acid amplification tests (NAATs). Accurate detection of *M. genitalium* is important for the treatment of symptomatic infections, as many strains of *M. genitalium* have developed resistance to the empirical treatments for urethritis or cervicitis (3, 8, 13, 19, 24–27; [www.cdc.gov/std/tg2015/emerging.htm#myco](http://www.cdc.gov/std/tg2015/emerging.htm#myco)).

Despite its relatively high prevalence compared with other STIs such as gonorrhea, screening for *M. genitalium* infections in asymptomatic individuals is not recommended due to our limited understanding of the consequences of asymptomatic infection and the need for antimicrobial stewardship (i.e., not treating infections that may naturally clear without harm). Only targeted testing of symptomatic or high-risk individuals is recommended by the currently published guidelines for STI screening and treatment (3; [www.cdc.gov/std/tg2015/emerging.htm#myco](http://www.cdc.gov/std/tg2015/emerging.htm#myco)). In the United States, there are currently only two FDA-approved diagnostic tests for the detection of *M. genitalium* in urogenital specimens: the Aptima *M. genitalium* (APT MG) assay (Hologic, Inc., San Diego, CA) and the Roche cobas *Trichomonas vaginalis* (TV)/MG assay (cobas) ([www.cdc.gov/std/tg2015/emerging.htm#myco](http://www.cdc.gov/std/tg2015/emerging.htm#myco); [www.cdc.gov/std/stats17/gonorrhea.htm](http://www.cdc.gov/std/stats17/gonorrhea.htm); <https://diagnostics.roche.com/us/en/news-listing/2019/roche-receives-fda-clearance-to-expand-testing-menu-on-cobas-6800-8800-systems-for-sexually-transmitted-diseases.html>; <https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-first-test-aid-diagnosis-sexually-transmitted-infection-known-mycoplasma>). In 2015, the U.S. Centers for Disease Control and Prevention (CDC) recognized *M. genitalium* infections as an emerging concern and described the need for improvements in the diagnosis and treatment of these infections ([www.cdc.gov/std/tg2015/emerging.htm#myco](http://www.cdc.gov/std/tg2015/emerging.htm#myco)). The British Association for Sexual Health and HIV (BASHH) and the International Union Against Sexually Transmitted Infections (IUSTI) both recommend that symptomatic patients should be tested for *M. genitalium* infection using NAAT technologies (3, 28). The objective of this multicenter study was to evaluate the clinical performance of the cobas test for the detection of *M. genitalium*, using urogenital specimens from both symptomatic and asymptomatic men and women.

## MATERIALS AND METHODS

**Patient population and ethics.** This multicenter study enrolled 2,194 participants  $\geq 14$  years of age who reported sexual activity within the previous 6 months. Participants attending family planning, obstetrics and gynecology, and STI clinics were recruited from geographically diverse sites in the United States: Birmingham (Alabama), Indianapolis (Indiana), Jackson (Mississippi), Miami (Florida), New Haven (Connecticut), New Orleans (Louisiana), Oakland (California), Providence (Rhode Island), and St. Louis (Missouri) (Fig. S1).

Participants were classified as demonstrating signs of infection if they reported any of the following symptoms: dysuria, coital issues (pain, difficulty, or bleeding), pelvic pain, abnormal vaginal discharge, unusual vaginal odor pelvic, uterine or ovarian pain, penile discharge, testicular pain, scrotal pain, or swelling, itching, burning, and redness or soreness of the genitals.

Patients were ineligible if they had previously enrolled in the study; used antimicrobial agents active against *M. genitalium* (doxycycline, macrolides including azithromycin and erythromycin, or fluoroquinolones including ofloxacin, ciprofloxacin, and levofloxacin) within the 21 days prior to sample collection; used Replens (Church & Dwight, Co., Inc., Princeton, NJ), RepHresh Odor Eliminating Vaginal Gel, RepHresh Clean and Balance (Church & Dwight, Co., Inc., Princeton, NJ), or products containing metro-

nidazole within 3 days prior to specimen collection; had undergone a full hysterectomy; or had a contraindication to the Papanicolaou test or cervical sampling.

This study was conducted in compliance with the International Conference on Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), Good Clinical Practice Guidelines (GCP), and applicable FDA regulations, and all participating subjects provided written informed consent. Institutional Review Board approval was obtained from each participating study site prior to the start of the study.

**Specimen collection.** Women provided specimens in the following order: first-catch urine (FCU), vaginal swabs, an endocervical swab in cobas PCR media, and a cervical specimen in PreservCyt solution obtained with a spatula, cytobrush, or broom. Participants were randomized to either self-obtained or clinician obtained for collection of vaginal swabs used in the cobas assay.

Participants within the self-collected arm had their self-collected vaginal swab collected first, and the remaining swabs were clinician collected. In the clinician-collected arm, all vaginal swabs were clinician collected. Following collection, the clinician transferred the swabs to the relevant transport media, as per the respective laboratory's standard operating procedures, for the validated APT MG assay (Hologic, San Diego, CA) and two *M. genitalium* laboratory-developed tests (LDTs) (29–31). Participants within the clinician-collected arm had an additional clinician-collected specimen for use with the cobas test. Both the endocervical swab and the liquid-based cytology (LBC) sample were collected for assessment with the cobas assay only.

Men first provided meatal swabs (self- or clinician collected) for use with the cobas test, followed by an FCU sample. The FCU sample was aliquoted into the manufacturer's collection device for use with APT MG, the two other *M. genitalium* LDTs, and the cobas assay.

**Sample testing.** The cobas assay was tested on either the cobas 6800 or 8800 system (detection of *M. genitalium* with the cobas assay is FDA cleared for female urine, self- and clinician-collected vaginal swabs, endocervical swabs, male urine, and male meatal swabs only). Specimens from each subject were tested using the cobas assay at a single test site. Samples for comparator methods were tested at sites based on the availability of the comparator instrument system and method. Samples were coded to ensure they were anonymized and to reduce bias. Testing was performed with each method according to the validated laboratory procedure (for the three LDTs). One of the *M. genitalium* LDTs was a real-time PCR assay that targeted the *mgpA* gene of *M. genitalium* (29, 30). The other *M. genitalium* LDT was a quantitative PCR designed to target the 23S rRNA gene of *M. genitalium* (31). The APT MG assay detects the 16S rRNA of *M. genitalium*.

**Patient infected status.** The patient infected status (PIS) was determined from vaginal swabs (women) and FCU (men) assayed in two *M. genitalium* laboratory-developed NAATs and the APT MG assay. If a participant had two or more positive results, the PIS was "positive," and at least two negative results defined the "not infected" classification. Any other combinations of valid results with invalid results were considered "indeterminate." Performance estimates for all sample types were based on comparison to these PIS classifications.

**Data analysis and interpretation of results.** Test results for each assay were interpreted according to the testing laboratory's standard operating procedures (SOP) and validation for their respective *M. genitalium* assay. Results were deemed invalid if there were protocol deviations, incidents, or if the data were generated during troubleshooting of the instrument or assays. All data analyses were performed using SAS/STAT software (32).

The clinical performance of the cobas test for the detection of *M. genitalium* was evaluated by comparing test results to the PIS. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated overall, for each gender, and by specimen type and symptom status and were compared with the infected status. The two-sided 95% confidence intervals (CIs) were provided for the estimates of sensitivity, specificity, PPV, and NPV. Significance was defined using Z-test analysis with  $\alpha = 0.05$ .

## RESULTS

**Subject disposition.** Of the 2,194 participants enrolled in the study, a total of 2,154 were considered eligible, and 2,150 were evaluated (1,104 female and 1,046 male) for the assessment of *M. genitalium* infection (Table 1). Evaluable urine samples were available from 1,099 female and 1,045 male participants. Clinician-collected and self-collected vaginal swabs were available in 551 and 550 participants, respectively. Clinician-collected and self-collected penile meatal swabs were available from 516 and 522 participants, respectively. In total, 28 specimens were excluded from the analysis: 5 female urine, 2 clinician-collected vaginal swabs, 1 self-collected vaginal swab, 6 PreservCyt, 5 endocervical swabs, 1 male urine, 2 clinician-collected meatal swabs, 2 self-collected meatal swabs, and 4 meatal swabs without collection information.

**Assay performance for the detection of *M. genitalium*.** In total, 59 women and 60 men were considered infected as determined by PIS analysis. Of these infected participants, 67.8% of women and 51.7% of men reported symptoms. The sensitivity, specificity, PPV, and NPV of cobas for the detection of *M. genitalium* are shown in Table 2. The overall sensitivity of the cobas test for the detection of *M. genitalium* in women

**TABLE 1** Baseline demographics and characteristics

Characteristic	Value(s)
Total (n)	2,150
Male age, yrs (mean ± SD)	37.6 ± 13.6
Female age, yrs (mean ± SD)	34.2 ± 11.7
Male (n [%])	1,046 (48.7)
Female (n [%])	1,104 (51.3)
American Indian/Alaskan Native (n [%])	3 (0.1)
Asian (n [%])	13 (0.6)
Black/African American (n [%])	1,501 (69.8)
Native Hawaiian/Pacific Islander (n [%])	5 (0.2)
White (n [%])	553 (25.7)
Multiple/other (n [%])	55 (2.6)
Not reported (n [%])	20 (0.9)
Symptomatic (n [%])	984 (45.8)
Asymptomatic (n [%])	1,166 (54.2)
Pregnant (female only) (n [%])	3 (0.3)
No. (%) of patients at a(n):	
Family planning clinic	525 (24.4)
Obstetrics/gynecology clinic	273 (12.7)
STI clinic	758 (35.2)
Family planning/STI clinic	594 (27.6)

was highest in vaginal swab samples (96.6% [95% CI, 88.5 to 99.1]; clinician and self-collected combined). The overall sensitivity of the test for female urine, PreservCyt samples, and endocervical samples ranged from 83.1% to 86.4% (Table 2). The overall sensitivity of cobas for *M. genitalium* in male urine samples and meatal swab samples was 100% (95% CI, 94.0 to 100%) and 85.0% (95% CI, 73.9 to 91.9%), respectively. There were no statistically significant sensitivity differences between the clinician- and self-collected vaginal swabs (96.3% versus 96.9%, respectively;  $P > 0.99$ ) and meatal swabs (83.9% versus 86.2%, respectively;  $P > 0.99$ ) as determined by the Z-test analyses. Additional Z-test analyses similarly showed no statistically significant specificity differences between the clinician- and self-collected vaginal swabs (96.8% versus 97.3%, respectively;  $P = 0.63$ ) and meatal swabs (97.5% versus 98.2%, respectively;  $P = 0.74$ ). Venn diagrams comparing cobas *M. genitalium* positivity across all tests, regardless of PIS, in female urine, male urine, vaginal, and meatal swab samples are shown in Fig. 1. The specificity of the cobas assay for *M. genitalium* ranged from 96.0 to 99.8% across male and female symptomatic and asymptomatic samples (Table 2).

Based on PIS, *M. genitalium* prevalence was higher in symptomatic than asymptomatic patients, and the overall prevalence ranged from 5.4% to 5.8% across male and female specimens (Table 2). The PPV of the cobas for detection of *M. genitalium* was 58.6 to 94.7%, and the NPV was 98.7 to 100% across all specimen types evaluated. Additional analyses of *M. genitalium* (regardless of PIS) prevalence by age, gender, sample type, and study site are provided in Table S1 and S2.


## DISCUSSION

This multicenter study evaluated the clinical performance of the cobas test for the detection of *M. genitalium* in urine and genital swab samples from men and women. Male urine and female vaginal swab samples had the highest sensitivity and specificity for the detection of *M. genitalium* in this analysis. The evidence supporting optimal specimen collection for *M. genitalium* detection in urogenital specimens is evolving. Observed differences among specimen types may be associated with pathogenesis and anatomical location (33, 34). The prevalence of *M. genitalium* varied among female specimens (Table S2). However, the differences between specimen types for men were not significant. The only statistically significant differences among female samples were between cervical (PreservCyt) and endocervical swabs, which were significantly less sensitive compared with vaginal swabs (Table 2) ( $P < 0.0001$ ).

The cobas test for the detection of *M. genitalium* had similar performance when

**TABLE 2** Clinical performance compared with PIS by gender, sample type, and symptom status

Sample type	Total	Sensitivity % (no. of true positives detected by cobas MG/total no. of true positives)	95% CI	Specificity % (no. of true negative samples identified/total no. of true negatives)	95% CI	Prevalence (%)	PPV (%)	NPV (%)
<b>Female participants</b>								
<b>Urine</b>								
Symptomatic	636	85.0 (34/40)	70.9–92.9	96.0 (572/596)	94.1–97.3	6.3	58.6	99.0
Asymptomatic	463	89.5 (17/19)	68.6–97.1	98.4 (437/444)	96.8–99.2	4.1	70.8	99.5
Overall	1,099	86.4 (51/59)	75.5–93.0	97.0 (1,009/1,040)	95.8–97.9	5.4	62.2	99.2
<b>Vaginal swab (both clinician and self-collected)</b>								
Symptomatic	639	97.5 (39/40)	87.1–99.6	96.3 (577/599)	94.5–97.6	6.3	63.9	99.8
Asymptomatic	462	94.7 (18/19)	75.4–99.1	98.0 (434/443)	96.2–98.9	4.1	66.7	99.8
Overall	1,101	96.6 (57/59)	88.5–99.1	97.0 (1,011/1,042)	95.8–97.9	5.4	64.8	99.8
<b>PreservCyt samples</b>								
Symptomatic	638	80.0 (32/40)	65.2–89.5	97.8 (585/598)	96.3–98.7	6.3	71.1	98.7
Asymptomatic	460	94.7 (18/19)	75.4–99.1	99.8 (440/441)	98.7–100	4.1	94.7	99.8
Overall	1,098	84.7 (50/59)	73.5–91.8	98.7 (1,025/1,039)	97.8–99.2	5.4	78.1	99.1
<b>Endocervical swab</b>								
Symptomatic	637	85.0 (34/40)	70.9–92.9	97.7 (583/597)	96.1–98.6	6.3	70.8	99.0
Asymptomatic	462	78.9 (15/19)	56.7–91.5	99.3 (440/443)	98.0–99.8	4.1	83.3	99.1
Overall	1,099	83.1 (49/59)	71.5–90.5	98.4 (1,023/1,040)	97.4–99.0	5.4	74.2	99.0
<b>Male participants</b>								
<b>Urine</b>								
Symptomatic	343	100 (31/31)	89.0–100	96.8 (302/312)	94.2–98.2	9.0	75.6	100
Asymptomatic	702	100 (29/29)	88.3–100	97.9 (659/673)	96.5–98.8	4.1	67.4	100
Overall	1,045	100 (60/60)	94.0–100	97.6 (961/985)	96.4–98.4	5.7	71.4	100
<b>Meatal swab (both clinician- and self-collected)</b>								
Symptomatic	343	90.3 (28/31)	75.1–96.7	96.5 (301/312)	93.8–98.0	9.0	71.8	99.0
Asymptomatic	695	79.3 (23/29)	61.6–90.2	98.5 (656/666)	97.3–99.2	4.2	69.7	99.1
Overall	1,038	85 (51/60)	73.9–91.9	97.9 (957/978)	96.7–98.6	5.8	70.8	99.1



**FIG 1** Venn diagrams comparing *M. genitalium*-positive female urogenital samples (A) and male urogenital samples (B). These data show exclusively cobas *M. genitalium*-positive results, as each sample type was not tested by all comparator assays.

assessed in both self-collected and clinician-collected vaginal or meatal swabs. This is important, as self-collection allows patients who are not comfortable with visiting a clinic or clinician collection access to effective testing. Across the STI testing field, self-testing has provided increased access to testing for patients who otherwise may not have received testing and is considered to have similar performance to testing with clinician-collected samples (35–38).

Specificity is important to ensure a patient is truly positive for the test infection. This is particularly important when introducing new NAATs to become the standard of care when gold-standard culture tests have historically been unavailable. The specificity of the cobas TV/MG test for the detection of *M. genitalium* was high regardless of the sample type or symptom status (Table 2), indicating the ability to perform well in different patient populations. In the absence of a reliable gold-standard test for the detection of *M. genitalium*, the first FDA-approved assay (Hologic Aptima) was validated by comparison to three alternate thermomechanical analysis (TMA) LDTs (18, 39). Here, we provide a similar evidence base for the cobas assay, allowing comparison with three validated LDTs (two PCR and one TMA-based method). Table 3 shows the head-to-head comparisons of cobas with the individual *M. genitalium* LDT NAATs for the U.S. prospective clinical study and highlights the variability that may be observed with different laboratories using validated LDTs for diagnosis of a suspected *M. genitalium* infection.

This prospective clinical study assessed the performance of the cobas assay for detecting *M. genitalium* among both symptomatic and asymptomatic patients. Current

**TABLE 3** Agreement of cobas for *M. genitalium* with each NAAT

Test or statistic	No. with NAAT1 test result of:			No. with NAAT2 test result of:			No. with NAAT3 test result of:		
	<i>M. genitalium</i> positive <sup>a</sup>	<i>M. genitalium</i> -negative NAAT1	Total	<i>M. genitalium</i> positive <sup>b</sup>	<i>M. genitalium</i> negative	Total	<i>M. genitalium</i> positive <sup>c</sup>	<i>M. genitalium</i> -negative NAAT3	Total
Vaginal swabs									
<i>M. genitalium</i> positive	36	52	88	55	33	88	88	0	88
<i>M. genitalium</i> negative	13	999	1,012	10	1,002	1,012	26	986	1,012
Total	49	1,051	1,100	65	1,035	1,100	114	986	1,100
PPA (% [95% CI])	73.5 (59.7–83.8)			84.6 (73.9–91.4)			77.2 (68.7–83.9)		
NPA (% [95% CI])	95.1 (93.6–96.2%)			96.8 (95.6–97.7)			100 (99.6–100)		
OPA (% [95% CI]) <sup>d</sup>	94.1 (92.5–95.3)			96.1 (94.8–97.1)			97.6 (96.6–98.4)		
Male urine samples									
<i>M. genitalium</i> positive	57	27	84	52	32	84	79	5	84
<i>M. genitalium</i> negative	12	943	955	5	950	955	3	952	955
Total	69	970	1,039	57	982	1,039	82	957	1,039
PPA (% [95% CI])	82.6 (72.0–89.8)			91.2 (81.1–96.2)			96.3 (89.8–98.7)		
NPA (% [95% CI])	97.2 (96.0–98.1)			96.7 (95.4–97.7)			99.5 (98.8–99.8)		
OPA (% [95% CI])	96.2 (94.9–97.2)			96.4 (95.1–97.4)			99.2 (98.5–99.6)		

<sup>a</sup>NAAT1 represents LDT 1 (targets the *mgbA* gene).

<sup>b</sup>NAAT2 represents LDT 2 (targets 23S rRNA).

<sup>c</sup>NAAT3 represents LDT3 (targets 16S rRNA).

<sup>d</sup>OPA, overall percentage agreement.

European and BASHH guidelines recommend testing of symptomatic individuals, but it is left to the discretion of the health care provider whether testing is warranted in those who are asymptomatic. In agreement with this study, the European and BASHH guidelines currently recommend that FCU samples in male participants and female vaginal swabs are the most sensitive sample types (3, 28). This study did not include anorectal samples in the evaluation since such studies should be conducted in more specialized clinical settings that provide services to men who have sex with men. This is an important area for future assay evaluations.

In this multicenter clinical study, the cobas assay had high sensitivity and specificity for the detection of *M. genitalium* in both male and female sample types, regardless of symptom status. This study provides evidence of a fully validated, high-throughput PCR assay for the detection of *M. genitalium*. Diagnostic solutions that include resistance markers in addition to the detection of the organism may be necessary in the near future. A useful aspect of the cobas 6800/8800 system is that LDTs can be rapidly developed and implemented on this platform, as reflex test options for *M. genitalium*-positive specimens are required (40).

**SUPPLEMENTAL MATERIAL**

Supplemental material is available online only.

**SUPPLEMENTAL FILE 1**, PDF file, 0.2 MB.

**ACKNOWLEDGMENTS**

We acknowledge the clinical staff for the subject enrollments and all the subjects who agreed to participate in this. We also thank the laboratory staff at the testing sites (Donna Crabb, Amy Ratliff, Miriam Mancuso, and Catherine Cammarata) and the clinical operations-biometrics staff for their assistance in the data provided for the manuscript (Merlin Njoya, Ravi Kammari).

Medical writing support was provided by Rose Falconer at Elements Communications, Westerham, United Kingdom, and was funded by Roche Molecular Diagnostics.

The findings and conclusions in this article are those of the authors and do not necessarily reflect the views of Planned Parenthood Federation of America, Inc.

This study was funded by Roche Molecular Systems, and several of the authors are employees of Roche Molecular Systems.



## REFERENCES

- Alfarraj DA, Somily AM. 2017. Isolation of *Mycoplasma genitalium* from endocervical swabs of infertile women. *Saudi Med J* 38:549–552. <https://doi.org/10.15537/smj.2017.5.18820>.
- Gottesman T, Yossepowitch O, Samra Z, Rosenberg S, Dan M. 2017. Prevalence of *Mycoplasma genitalium* in men with urethritis and in high risk asymptomatic males in Tel Aviv: a prospective study. *Int J STD AIDS* 28:127–132. <https://doi.org/10.1177/0956462416630675>.
- Jensen JS, Cusini M, Gomberg M, Moi H. 2016. 2016 European guideline on *Mycoplasma genitalium* infections. *J Eur Acad Dermatol Venereol* 30:1650–1656. <https://doi.org/10.1111/jdv.13849>.
- Madsen AMR, Thorsteinsson K, Lebech AM, Storgaard M, Katzenstein TL, Ronsholt FF, Johansen IS, Pedersen G, Nielsen LN, Andersen AB, Jensen JS. 2017. Prevalence and significance of *Mycoplasma genitalium* in women living with HIV in Denmark. *BMC Res Notes* 10:468. <https://doi.org/10.1186/s13104-017-2776-5>.
- Moi H, Reinton N, Moghaddam A. 2009. *Mycoplasma genitalium* in women with lower genital tract inflammation. *Sex Transm Infect* 85:10–14. <https://doi.org/10.1136/sti.2008.032748>.
- Moi H, Reinton N, Moghaddam A. 2009. *Mycoplasma genitalium* is associated with symptomatic and asymptomatic non-gonococcal urethritis in men. *Sex Transm Infect* 85:15–18. <https://doi.org/10.1136/sti.2008.032730>.
- Read TRH, Murray GL, Danielewski JA, Fairley CK, Doyle M, Worthington K, Su J, Mokany E, Tan LT, Lee D, Vodstrcil LA, Chow EPF, Garland SM, Chen MY, Bradshaw CS. 2019. Symptoms, sites, and significance of *Mycoplasma genitalium* in men who have sex with men. *Emerg Infect Dis* 25:719–727. <https://doi.org/10.3201/eid2504.181258>.
- Weinstein SA, Stiles BG. 2012. Recent perspectives in the diagnosis and evidence-based treatment of *Mycoplasma genitalium*. *Expert Rev Anti Infect Ther* 10:487–499. <https://doi.org/10.1586/eri.12.20>.
- Manhart LE, Holmes KK, Hughes JP, Houston LS, Totten PA. 2007. *Mycoplasma genitalium* among young adults in the United States: an emerging sexually transmitted infection. *Am J Public Health* 97:1118–1125. <https://doi.org/10.2105/AJPH.2005.074062>.
- Sonnenberg P, Ison CA, Clifton S, Field N, Tanton C, Soldan K, Beddows S, Alexander S, Khanom R, Saunders P, Copas AJ, Wellings K, Mercer CH, Johnson AM. 2015. Epidemiology of *Mycoplasma genitalium* in British men and women aged 16–44 years: evidence from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). *Int J Epidemiol* 44:1982–1994. <https://doi.org/10.1093/ije/dyv194>.
- Andersen B, Sokolowski I, Ostergaard L, Kjolseth Moller J, Olesen F, Jensen JS. 2007. *Mycoplasma genitalium*: prevalence and behavioural risk factors in the general population. *Sex Transm Infect* 83:237–241. <https://doi.org/10.1136/sti.2006.022970>.
- Baumann L, Cina M, Egli-Gany D, Goutaki M, Halbeisen FS, Lohrer GR, Ali H, Scott P, Low N. 2018. Prevalence of *Mycoplasma genitalium* in different population groups: systematic review and meta-analysis. *Sex Transm Infect* 94:255–262. <https://doi.org/10.1136/sextrans-2017-053384>.
- Asenjo A, Kusters JG, Severs TT, Alos JI. 2018. *Mycoplasma genitalium* in Spain: prevalence of genital infection and frequency of resistance to macrolides. *Enferm Infecc Microbiol Clin* 36:169–171. <https://doi.org/10.1016/j.eimc.2017.01.006>.
- Le Roux MC, Hoosen AA. 2017. Quantitative real-time polymerase chain reaction for the diagnosis of *Mycoplasma genitalium* infection in South African men with and without symptoms of urethritis. *Sex Transm Infect* 44:17–20. <https://doi.org/10.1097/OLQ.0000000000000540>.
- Napierala M, Munson E, Wenten D, Phipps P, Gremminger R, Schuknecht MK, Munson KL, Boyd V, Hamer D, Schell RF, Hryciuk JE. 2015. Detection of *Mycoplasma genitalium* from male primary urine specimens: an epidemiologic dichotomy with *Trichomonas vaginalis*. *Diagn Microbiol Infect Dis* 82:194–198. <https://doi.org/10.1016/j.diagmicrobio.2015.03.016>.
- Pereyre S, Laurier Nadalie C, Bebear C, Investigator Group. 2017. *Mycoplasma genitalium* and *Trichomonas vaginalis* in France: a point prevalence study in people screened for sexually transmitted diseases. *Clin Microbiol Infect* 23:122.e1–122.e7. <https://doi.org/10.1016/j.cmi.2016.10.028>.
- Tjagur S, Mandar R, Punab M. 2018. Prevalence of *Mycoplasma genitalium* and other sexually transmitted infections causing urethritis among high-risk heterosexual male patients in Estonia. *Infect Dis (Lond)* 50:133–139. <https://doi.org/10.1080/23744235.2017.1366044>.
- Unemo M, Salado-Rasmussen K, Hansen M, Olsen AO, Falk M, Golparian D, Aasterod M, Ringlander J, Nilsson CS, Sundqvist M, Schonning K, Moi H, Westh H, Jensen JS. 2018. Clinical and analytical evaluation of the new Aptima *Mycoplasma genitalium* assay, with data on *M. genitalium* prevalence and antimicrobial resistance in *M. genitalium* in Denmark, Norway and Sweden in 2016. *Clin Microbiol Infect* 24:533–539. <https://doi.org/10.1016/j.cmi.2017.09.006>.
- Golden MR, Workowski KA, Bolan G. 2017. Developing a public health response to *Mycoplasma genitalium*. *J Infect Dis* 216:S420–S426. <https://doi.org/10.1093/infdis/jix200>.
- Romano SS, Jensen JS, Lowens MS, Morgan JL, Chambers LC, Robinson TS, Totten PA, Soge OO, Golden MR, Manhart LE. 2018. Long duration of asymptomatic *Mycoplasma genitalium* infection after syndromic treatment for nongonococcal urethritis. *Clin Infect Dis* 69:113–120. <https://doi.org/10.1093/cid/ciy843>.
- Oakeshott P, Aghaizu A, Hay P, Reid F, Kerry S, Atherton H, Simms I, Taylor-Robinson D, Dohn B, Jensen JS. 2010. Is *Mycoplasma genitalium* in women the “new chlamydia?” A community-based prospective cohort study. *Clin Infect Dis* 51:1160–1166. <https://doi.org/10.1086/656739>.
- Ona S, Molina RL, Diouf K. 2016. *Mycoplasma genitalium*: an overlooked sexually transmitted pathogen in women? *Infect Dis Obstet Gynecol* 2016:4513089. <https://doi.org/10.1155/2016/4513089>.
- Taylor-Robinson D, Furr PM, Tully JG. 1983. Serological cross-reactions between *Mycoplasma genitalium* and *M. pneumoniae*. *Lancet* 1:527. [https://doi.org/10.1016/S0140-6736\(83\)92212-2](https://doi.org/10.1016/S0140-6736(83)92212-2).
- Deborde M, Pereyre S, Puges M, Bebear C, Desclaux A, Hessamfar M, Le Roy C, Le Marec F, Dabis F, Cazanave C. 2019. High prevalence of *Mycoplasma genitalium* infection and macrolide resistance in patients enrolled in HIV pre-exposure prophylaxis program. *Med Mal Infect* 49:347–349. <https://doi.org/10.1016/j.medmal.2019.03.007>.
- Fernandez-Huerta M, Serra-Pladevall J, Esperalba J, Espasa M. 2019. *Mycoplasma genitalium* and fluoroquinolone resistance: from genotype to phenotype. *Enferm Infecc Microbiol Clin* 38:44–45. <https://doi.org/10.1016/j.eimc.2019.04.007>.
- Hadad R, Golparian D, Lagos AC, Ljungberg J, Nilsson P, Jensen JS, Fredlund H, Unemo M. 2018. Macrolide and fluoroquinolone resistance in *Mycoplasma genitalium* in two Swedish countries, 2011–2015. *APMIS* 126:123–127. <https://doi.org/10.1111/apm.12792>.
- Sethi S, Zaman K, Jain N. 2017. *Mycoplasma genitalium* infections: current treatment options and resistance issues. *Infect Drug Resist* 10:283–292. <https://doi.org/10.2147/IDR.S105469>.
- Soni S, Horner P, Rayment M, Pinto-Sander N, Naous N, Parkhouse A, Bancroft D, Patterson C, Fifer H. 2018. British Association for Sexual Health and HIV national guideline for the management of infection with *Mycoplasma genitalium* (2018). British Association for Sexual Health and HIV, Cheshire, UK.
- Dehon PM, Hagensee ME, Sutton KJ, Oddo HE, Nelson N, McGowin CL. 2016. Histological evidence of chronic *Mycoplasma genitalium*-induced cervicitis in HIV-infected women: a retrospective cohort study. *J Infect Dis* 213:1828–1835. <https://doi.org/10.1093/infdis/jiw025>.
- Dehon PM, McGowin CL. 2014. *Mycoplasma genitalium* infection is associated with microscopic signs of cervical inflammation in liquid cytology specimens. *J Clin Microbiol* 52:2398–2405. <https://doi.org/10.1128/JCM.00159-14>.
- Xiao L, Waites KB, Wang H, Van Der Pol B, Ratliff AE, Geisler WM. 2018. Evaluation of a real-time PCR assay for detection of *Mycoplasma genitalium* and macrolide resistance-mediating mutations from clinical specimens. *Diagn Microbiol Infect Dis* 91:123–125. <https://doi.org/10.1016/j.diagmicrobio.2018.02.002>.
- Food and Drug Administration. 2007. Statistical guidance on reporting results from studies evaluating diagnostic tests - guidance for industry and FDA staff. Food and Drug Administration, Washington, DC.
- Dehon PM, McGowin CL. 2017. The immunopathogenesis of *Mycoplasma genitalium* infections in women: a narrative review. *Sex Transm Infect* 44:428–432. <https://doi.org/10.1097/OLQ.0000000000000621>.
- Coorevits L, Traen A, Binge L, Van Dorpe J, Praet M, Boelens J, Padalko E. 2018. Identifying a consensus sample type to test for *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, *Mycoplasma genitalium*, *Trichomonas vaginalis* and human papillomavirus. *Clin Microbiol Infect* 24:1328–1332. <https://doi.org/10.1016/j.cmi.2018.03.013>.
- Buhrer-Skinner M, Muller R, Buettner PG, Gordon R, Debattista J. 2013. Reducing barriers to testing for *Chlamydia trachomatis* by mailed self-

- collected samples. *Sex Health* 10:32–38. <https://doi.org/10.1071/SH11065>.
36. Ogale Y, Yeh PT, Kennedy CE, Toskin I, Narasimhan M. 2019. Self-collection of samples as an additional approach to deliver testing services for sexually transmitted infections: a systematic review and meta-analysis. *BMJ Glob Health* 4:e001349. <https://doi.org/10.1136/bmjgh-2018-001349>.
  37. Gaydos CA, Manhart LE, Taylor SN, Lillis RA, Hook EW, 3rd, Klausner JD, Remillard CV, Love M, McKinney B, Getman DK. 2019. Molecular testing for *Mycoplasma genitalium* in the United States: results from the AMES Prospective Multicenter Clinical Study. *J Clin Microbiol* 57:e01125-19. <https://doi.org/10.1128/JCM.01125-19>.
  38. Marlowe EM, Gohl P, Steidle M, Arcenas R, Bier C. 2019. *Trichomonas vaginalis* detection in female specimens with cobas TV/MG for use on the cobas 6800/8800 systems. *Eur J Microbiol Immunol (Bp)* 9:42–45. <https://doi.org/10.1556/1886.2019.00004>.
  39. Le Roy C, Pereyre S, Hénin N, Bébéar C. 2017. French prospective clinical evaluation of the Aptima *Mycoplasma genitalium* CE-IVD assay and macrolide resistance detection using three distinct assays. *J Clin Microbiol* 55:3194–3200. <https://doi.org/10.1128/JCM.00579-17>.
  40. Van Der Pol B. 2020. A profile of the cobas TV/MG test for the detection of *Trichomonas vaginalis* and *Mycoplasma genitalium*. *Expert Rev Mol Diagn* 20:381–386. <https://doi.org/10.1080/14737159.2020.1714440>.